Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03671642
Other study ID # H-18006334
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 8, 2018
Est. completion date March 11, 2019

Study information

Verified date March 2019
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate a new method to assess tissue perfusion during surgery for esophageal cancer.

When a tumor in the distal esophagus is removed, the ends of the esophagus and the stomach must be reconnected by an anastomosis. An optimal perfusion is essential to ensure a good healing of the anastomosis. If anastomotic leakage occurs, it may prolong hospital stay, increase the risk of serious complications and death, delay start-up of chemotherapy and worsen the long-term survival prognosis.

During the operation the blood supply to the ends of the esophagus and stomach will be assessed in different ways; The traditional where the surgeon looks and feels on the tissue, and newer methods with an indocyanine green and cameras that illuminate the tissue with near-infrared light. The surgeon will assess whether these methods change the decision on where the ends should be sewn together.


Description:

Introduction:

An optimal perfusion is essential in gastrointestinal surgery when resection of a cancerous tissue requires an anastomosis, since impaired perfusion seems to be associated with increased risk of anastomotic leakage (AL). AL is a severe complication with the risk of; prolonged hospital stay, cancer recurrence, permanent stoma in colorectal surgery, and increased short and long-term mortality. To avoid poor perfusion of an anastomosis, perfusion assessment is necessary during the operative procedure. Traditionally, perfusion is assessed visually and manually by the surgeon by judging the; color of the tissue, bleeding from the resection line, and the arterial supply pulse by palpation. These methods have earlier been shown to be unreliable and prone to observer bias. Furthermore, palpation of arterial supply is not possible in laparoscopic or robot-assisted surgery, and the increased use of staplers to divide the bowel leaves no bleeding resection lines. Therefore newer methods for perfusion assessment have been investigated, and fluorescence angiography (FA) and laser speckle contrast imaging (LSCI) has shown very promising results. In a systematic review of nonrandomized studies, the leakage rate in 916 colorectal resections was significantly lower when using FA compared to controls (3.3%, [95% CI: 1.97-4.63%] vs 8.5%, [95% CI: 4.8-12.2%], p=0.0055).

In FA, the tissue of interest is exposed to near-infrared (NIR) light simultaneously with intravenous injection of a fluorescent dye. When the dye reaches the illuminated area, it fluoresces, and a camera with a special filter can visualize the microcirculation of the tissue on a monitor. Many NIR-camera systems are on the market, combining the technique with conventional laparoscopic or robotic equipment, and several non-randomized studies have indicated that FA may reduce the anastomotic leakage rate in gastrointestinal surgery. Most surgeons are using only a visual subjective assessment of the FA, which may be prone to observer bias. Moreover, if the camera is not held at a standard distance from the tissue, or a different concentration of dye is used, a false negative or positive assessment of the perfusion may be made. Therefore, it has been argued that there is a need for an objective unbiased quantitative assessment tool in FA.

A quantification algorithm that provides a fluorescence-time curve and a quantitative parameter of perfusion, the normalized slope has previously been published, where a nearly linear correlation to regional flow was found. Until now measurements has been performed as analyses of video-recordings after the procedure.

In order to use the method in a clinical setting, development and testing of a tool that may be operated by the surgeon during the procedure to perform perioperative measurements is of high importance. A touchscreen tablet has been developed, in order to perform live perioperative quantitative perfusion assessment using FA. The tool may be used with several systems including Karl Storz fluorescence laparoscopic equipment and the daVinci SI or XI from Intuitive. This tool is essential in order to implement the technology into daily practice, as it allows the surgeon to get an immediate quantitative parameter of perfusion (normalized slope) at desired regions of interest. The interface of the tool should be easy to use and provide fluorescence-time curves to control the automated calculation of the normalized slope. In addition, a color-coded map of perfusion intensity should be provided as an overlay on the white light picture of the bowel investigated.

Aim:

The touchscreen tablet has currently only been tested in animal surgery. The aim of the present study is to investigate if the use of a perioperative quantitative perfusion assessment tool may improve the perfusion assessment during surgery in humans.

Hypotheses:

- Perioperative perfusion assessment with FA will change the point of resection determined by conventional visual perfusion assessment in GI junctional procedures.

- Quantitative perfusion assessment with FA (Q-ICG) will further change the point of resection determined by visual assessment of the FA and conventional visual assessment of perfusion in GI junctional procedures.

Primary endpoints:

- Feasibility of perfusion assessment with traditional visual, visual FA, and Q-ICG - complied by completion rates.

- The feasibility and usability of the tool, the surgeons' experiences with the Q-ICG-tablet interface - rated on a validated questionnaire, the System Usability Scale.

Secondary endpoints:

• Differences in the distance from the determined resection points using traditional assessment, FA, and Q-ICG.

Methods

Study Design:

The study will be conducted as an observational feasibility and usability trial in patients undergoing open or robot-assisted resection of the gastroesophageal junction (GI junction) in a single university hospital center (Rigshospitalet, Department of Surgical Gastroenterology). Patients will serve as their own control. Demographic information (tumor-staging, gender, age, BMI, neoadjuvant treatment, ASA-classification, smoking, alcohol, medication etc.) will be collected from the electronic patient records. In addition, postoperative events, especially the presence of an anastomotic leakage, will be noted 30 days postoperatively. No formal sample size calculation has been performed as the study is a feasibility study. 20 patients will be included. Participating patients will receive the same standard post- and peri-operative care and follow-up as patients not included in the study.

Indocyanine green Indocyanine green (ICG) is a well-described nontoxic tricarbocyanine dye used for decades in ophthalmology, cardiology, and hepatology. Very few mild adverse reactions have been reported, but caution in patients with thyrotoxicosis, allergy towards iodine or indocyanine green should be made. When injected intravenously it binds to blood lipoproteins and is solely metabolized by the liver and excreted in the bile, with a short half-life of approximately 4-5 minutes.

Surgical procedure and perfusion assessment When the dissection and division of the feeding blood vessels are complete and the gastric conduit established and drawn to the thorax, the gastrointestinal surgeon will choose the most proximal point possible on the conduit for the anastomosis (Anastomotic point surgeon, APS) by pointing while a picture is captured, blinded for the thoracic surgeon. A sterile paper ruler will be introduced to the thorax, in order to measure the distance between the chosen resection points. Then, LSCI measurement of the conduit is performed, and finally, a bolus of ICG (0.25 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline, and the tissue of interest exposed to NIR-light (excitation wavelength 750-800 nm) and emission observed at 800 nm (FA). During the video-captures of LSCI and ICG-FA, the respiration will be paused for a maximum of 20 seconds initiated at the moment of saline injection. After the FA the thoracic surgeon will by visual assessment determine and mark a new anastomotic point by pointing at the most proximal point possible on the conduit for the anastomosis, while a picture is taken (anastomotic point fluorescence angiography, APFA). After the quantitative FA the surgeon will again mark an anastomotic point (APQFA). The final anastomotic point will be chosen by the primary gastrointestinal and the thoracic surgeon, and if the assessment of FA or quantitative FA will influence this decision is solely up to the surgeon. The same points will be marked on the LSCI picture but not revealed to the surgeon since the quantitative assessment of the LSCI demands on post hoc data-analysis.

When the surgeon decides how much tissue to resect to ensure an optimal anastomotic perfusion, care must be taken not to cause tension to the anastomosis by resecting too much of the gastric conduit or the esophagus, as tension is a known risk factor of anastomotic leakage. Again, the level of resection is solely decided by the surgeon and this decision should, as always, be made by balancing factors of tension, perfusion, and excessive tissue loss - all combined to ensure an optimal anastomotic healing.

Laparoscopic fluorescence angiography A laparoscope (ICG-Hopkins telescope 30°, 10 mm, Karl Storz Gmbh and Co. KG, Tüttlingen, Germany) will be connected to a camera system (IMAGE1, Karl Storz Gmbh and Co. KG, Tüttlingen, Germany) and a light-source (D-light P, Karl Storz Gmbh and Co. KG, Tüttlingen, Germany) will supply the excitatory light and record the FA. The laparoscope will be fixed in a mechanical holding arm 10 cm from the tissue of interest, ensuring a stable position throughout the experiment.

Robot-assisted fluorescence angiography A surgical robot DaVinci SI (Intuitive Surgical Inc., Sunnyvale, CA, USA) and the Firefly Fluorescence Imaging system will be used. The camera will be fixed 10 cm from the tissue of interest, ensuring a stable position throughout the experiment.

Quantitative fluorescence angiography (Q-ICG) A video capture device (Av.io HD™, Epiphan video, California, USA) will be connected to the surgical robot or the laparoscopic camera system and transfer the video capture to a tablet (Microsoft Surface Pro4 I5, Microsoft, Redmond, WA, USA). A program developed to quantify the FA will be installed. Here the operator can choose regions of interest to quantify from the captured video sequence. A color grading of perfusion will be provided as well as quantitative values from specific points. From this assessment, the surgeon will again determine a new resection point (APQFA).

Comparison of resection points The distance from the tumor to the RPS will be measured before the FA using the paper ruler. In addition, the distance from the APS to APFA and APQFA will be measured using the ruler, either during the procedure or post hoc using the video-capture. The comparison of the distance will be made on the distance of each point from the tumor.

Feasibility The feasibility will be investigated by comparison of completion rates of the different perfusion assessment methods; traditional, FA, Q-ICG.

Usability The usability of the quantitative perfusion assessment tool will be investigated with a validated questionnaire, the System Usability Scale, answered by the surgeon immediately after the procedure.

Statistics Comparison of data will be performed using Mann Whitney U test or a paired sample t-test depending on distribution normality. P-values < 0.05 is considered significant. No formal sample size calculation has been made, as the study is considered a feasibility trial. 20 patients will be recruited. Statistic evaluation was performed using IBM SPSS Statistics © (v 22.0 SPSS Inc. Chicago, IL, USA).

Adverse events, risks, and disadvantages Adverse events associated with the use of ICG are extremely rare and severe anaphylactic reactions are almost never occurring. However, safety precautions have been made by excluding patients with allergy to iodine, ICG or shellfish. In addition, no patients with liver insufficiency, thyrotoxicosis, ongoing pregnancy, or lactating women will be included.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date March 11, 2019
Est. primary completion date March 11, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients (above 18 years) scheduled for planned open or robot-assisted resection of the gastroesophageal junction (GI junction) for GI junctional cancer.

Exclusion Criteria:

- Allergy towards; iodine, indocyanine green or shellfish

- Liver insufficiency

- Thyrotoxicosis

- Pregnancy or lactation

- Legally incompetent for any reason

- Withdrawal of inclusion consent at any time

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Q-ICG
Quantitative perfusion assessment with indocyanine green on a touch screen tablet
Procedure:
White light perfusion assessment
Traditional visual perfusion assessment in white light
Fluorescence angiography
Perfusion assessment with fluorescence angiography - without quantification

Locations

Country Name City State
Denmark Department of Surgical Gastroenterology - Rigshospitalet Copenhagen Ø

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Nerup N, Andersen HS, Ambrus R, Strandby RB, Svendsen MBS, Madsen MH, Svendsen LB, Achiam MP. Quantification of fluorescence angiography in a porcine model. Langenbecks Arch Surg. 2017 Jun;402(4):655-662. doi: 10.1007/s00423-016-1531-z. Epub 2016 Nov 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Completion rates Feasibility of perfusion assessment with traditional visual, visual FA, and Q-ICG during surgery
Secondary Differences in resection points Differences in the distance from the determined resection points using traditional assessment, LSCI, FA, and quantitative FA. up to 6 months
Secondary System Usability Scale The feasibility and usability of the tool, the surgeons' experiences with the Q-ICG tablet interface - rated on a validated questionnaire, the System Usability Scale - https://www.usability.gov/how-to-and-tools/methods/system-usability-scale.html.
Scores ranges from 0-100, where a score of 68 is considered average.
up to one week
See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02544737 - Apatinib for Metastatic Esophageal Cancer. Phase 2